Your search matched 27 results
You think you’re busy?
Winter is coming… in May.
Climate change is named a top 10 health threat and we’ve broken down the conundrum for pharma companies regarding activating on the issue.
SCOTUS is weighing its options on a number of healthcare cases; using social activism to tip the scales for your brand reputation; and crowdfunding for what?
The Week That Was: ... | Blog
Our favorite #healthpolicyvalentines, new FDA guidance regarding complex generics and what you need to know now regarding data security from pharma and patient perspectives.
Policymakers continue their focus on drug pricing and may also have eyes for changes to the Orphan Drug Act.
Missed BIO 2019?
What do vacationers on a cruise ship in St.
As drug pricing continues to be under the microscope, it’s a tough environment for drug makers.
This week's edition of The Week That Was details how health and medical groups are taking action to address the “greatest public health challenge of the 21st century” and what you need to know from a busy week in healthcare policy.
“Timing is everything - particularly when lives are at stake.”
80% of voters support importing drugs from Canada and politicians on both sides of the aisle agree.
A recent survey found 70% of investors decreased interest in buying IPOs compared to last spring.
It’s seems like it’s being marketed as a treatment for everything from pain to anxiety, but is it legal?
Congress is back from summer recess and healthcare is top of mind.
This week’s edition of The Week That Was details how the Business Roundtable’s “Statement on the Purpose of a Corporation” shifts businesses’ focus from solely shareholders to all stakeholders.
How could the recent impeachment inquiry effect drug pricing legislation on the Hill?
The FDA is expecting to receive more than 200 investigational new drug applications per year for gene therapies, starting in 2020.
Missed the most recent analysis conducted by ICER?
Are U.S. sheriffs PhRMA’s new spokespeople?
It’s been a little over a year since the first crash of a Boeing 737 Max in Indonesia.
How will the Institute for Clinical and Economic Review (ICER) reconcile the tug-of-war between the promise and uncertainty in valuing gene therapies?
From potential drug pricing policies to investor interest in life science companies, there’s a lot of talk around money and medicines right now.
A consortium of 300 powerful organizations have filed resolutions demanding research into the feasibility of tying drug pricing to senior executive incentive pay.
On Wednesday, the House Energy & Commerce Committee held a hearing on safeguarding pharmaceutical supply chains in a global economy, and the discussion included something for everyone.